Original Articles, FREQUENCY OF THROMBOCYTOPENIA AMONG DIFFERENT AGE GROUPS OF PATIENTS WITH LIVER CIRRHOSIS.
Keywords:
Thrombocytopenia, Liver cirrhosis, Chronic Hepatitis, plateletsAbstract
Objectives
Patients with cirrhosis frequently exhibit thrombocytopenia, which might prompt an unnecessary referral for a bone marrow biopsy. The frequency of thrombocytopenia in liver cirrhosis is largely unknown in the study area. The main aim of our study is to evaluate prevalence thrombocytopenia in such patients in the study area.
Methods
A retrospective cross-sectional study was conducted on 268 confirmed liver cirrhosis patients for thrombocytopenia in Khyber teaching hospital, Peshawar. Both, male and female subjects with establish liver cirrhosis were included in the study while Patients having concurrent illness which can induce thrombocytopenia like malaria, dengue fever, ITP, malignancy. This study takes a total of six months duration. Data analysis was done using SPSS software for Windows (Version 20.0, SPSS Inc. Chicago).
Results
Results showed that 74.8% of the studied subjects were diagnosed with thrombocytopenia while 25.2% were normal. Thrombocytopenic patients were also categorized into mild, moderate, and severe. Among different age groups, severe thrombocytopenia was found to be highest in all age groups having 113 (42.2%) subjects. Consequently, Severe thrombocytopenia in age group 51-60 years were diagnosed in 99 (36.9%) cirrhosis patients which is statistically significant with p-value =0.032. In addition, 56 (20.9%) of the age group 31–40 year age were diagnosed for severe thrombocytopenia.
Conclusion
Our study concluded that thrombocytopenia showed be the primary parameter while to check for complications, related to liver cirrhosis.
References
Sheikh MY, Raoufi R, Atla PR, Riaz M, Oberer C, Moffett MJ. Prevalence of cirrhosis in patients with thrombocytopenia who receive bone marrow biopsy. Saudi Journal of Gastroenterology: Official Journal of the Saudi Gastroenterology Association. 2012;18(4):257.
Aster R. Pooling of platelets in the spleen: role in the pathogenesis of. The Journal of clinical investigation. 1966;45(5):645-57.
Giannini E, Borro P, Botta F, Fumagalli A, Malfatti F, Podestà E, et al. Serum thrombopoietin levels are linked to liver function in untreated patients with hepatitis C virus-related chronic hepatitis. Journal of hepatology. 2002;37(5):572-7.
Mayer M, Herrmann I, Kempgens U, Queisser W. In Vivo Labeling of Platelets with 75Se–Selenomethionine in Patients with Hepatic Cirrhosis and Thrombocytopenia. Thrombosis and Haemostasis. 1977;37(01):047-52.
Rios R, Sangro B, Herrero I, Quiroga J, Prieto J. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Official journal of the American College of Gastroenterology| ACG. 2005;100(6):1311-6.
Weksler B. the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Alimentary pharmacology & therapeutics. 2007;26:13-9.
Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, et al. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47(3):789-98.
Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy-a review of UK data for 2004. Haematologica. 2006;91(9):1293-4.
Vanhelleputte P, Nijs K, Delforge M, Evers G, Vanderschueren S. Pain during bone marrow aspiration: prevalence and prevention. Journal of pain and symptom management. 2003;26(3):860-6.
Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. New England Journal of Medicine. 2010;363(14):1341-50.
Vernon G, Baranova A, Younossi Z. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults. Alimentary pharmacology & therapeutics. 2011;34(3):274-85.
Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. Journal of hepatology. 2008;49(4):608-12.
Qamar AA, Grace ND, Groszmann RJ, Garcia–Tsao G, Bosch J, Burroughs AK, et al. Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. Clinical Gastroenterology and Hepatology. 2009;7(6):689-95.
Rosati S, Mick R, Xu F, Stonys E, Le Beau M, Larson R, et al. Refractory cytopenia with multilineage dysplasia: further characterization of an'unclassifiable'myelodysplastic syndrome. Leukemia. 1996;10(1):20-6.
Sun Y, Lan X, Shao C, Wang T, Yang Z. Clinical features of idiopathic portal hypertension in China: A retrospective study of 338 patients and literature review. Journal of Gastroenterology and Hepatology. 2019;34(8):1417-23.
Jäger U, Barcellini W, Broome CM, Gertz MA, Hill A, Hill QA, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus Meeting. Blood reviews. 2020;41:100648.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966-84.
Blackburn LM, Bender S, Brown S, editors. Acute leukemia: diagnosis and treatment. Seminars in oncology nursing; 2019: Elsevier.
Lupia E, Capuano M, Vizio B, Schiavello M, Bosco O, Gelardi M, et al. Thrombopoietin participates in platelet activation in COVID-19 patients. EBioMedicine. 2022;85:104305.
Yu H, Wang X, Liu L, Chen B, Feng S, Lu X, et al. Thrombopoietin receptor agonist eltrombopag prevents insulin resistance-mediated synaptic pathology via HIF1α/GSK3β/Sirt1 pathway. 2021.
Bosserman LD, Mambetsariev I, Ladbury C, Barzi A, Johnson D, Morse D, et al. Pyramidal Decision Support Framework Leverages Subspecialty Expertise across Enterprise to Achieve Superior Cancer Outcomes and Personalized, Precision Care Plans. Journal of Clinical Medicine. 2022;11(22):6738.
Younossi ZM, Corey KE, Alkhouri N, Noureddin M, Jacobson I, Lam B, et al. Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Alimentary pharmacology & therapeutics. 2020;52(3):513-26.
Henry L, Paik J, Younossi ZM. the epidemiologic burden of non‐alcoholic fatty liver disease across the world. Alimentary pharmacology & therapeutics. 2022;56(6):942-56.
